微泰醫療今日起招股,入場費約3146元
專注糖尿病研發的微泰醫療 (新上市編號:2235) 於週三(6日)至下週一(11日)中午招股。微泰醫療計劃發行6352.95萬股H股,其中10%爲香港公開發售,每H股作價最高31.15元,料淨集資額爲約18.5億。以微泰醫療每手100股計,一手入場費約3146.4元。
微泰醫療器械預計於10月19日掛牌。中金及高盛爲公司保薦人。
微泰醫療成立於2011年,專注於糖尿病管理,提供糖尿病治療及監測醫療器械,主要產品線包括貼敷式胰島素泵、持續血糖監測系統、死循環人工胰腺及體外診斷醫療器械設備等,核心產品Equil貼敷式胰島素泵已於2017年取得中國藥監局成人使用上市批準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.